Live
FierceBiotechFDA advisory committee set to weigh taking action on certain unapproved peptides10x Genomics BlogAfter the bell: 10x Genomics posts quarterly results May 7 - Stock Titan10x Genomics Blog10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026 - Yahoo FinanceEndpoints NewsScribing startup Abridge adds NEJM, JAMA as it moves into medical AI searchEndpoints NewsFDA weighs support for compounding popular peptidesEndpoints NewsBiotech stocks are on a tear againAgilentAgilent (A) Showcases Innovations at AACR 2026 Annual Meeting - GuruFocusBioPharma DiveBeeline, a Bain-backed biotech, debuts with immune drugs from Bristol MyersFierceBiotechLabcorp launches rapid fentanyl test with 48-hour detection windowFierceBiotechWas Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought?FierceBiotechSpain sets up Boston-focused VC fund with goal of raising $200M for biotechsFierceBiotechNovartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
FierceBiotech Apr 16, 2026

FDA advisory committee set to weigh taking action on certain unapproved peptides

FDA advisory committee set to weigh taking action on certain unapproved peptides

Original
Body unavailable. Use the original source.

Directory

1122 All